Enterprise Value
512.4M
Cash
322M
Avg Qtr Burn
-27.78M
Short % of Float
5.54%
Insider Ownership
7.76%
Institutional Own.
93.74%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KER-012 Details Pulmonary hypertension, Cardiovascular disease | Phase 2 Data readout | |
KER-050 Details Blood cancer, Cystic fibrosis, Lung disease, Myelofibrosis, Cancer | Phase 2 Data readout | |
KER-050 Details Blood disorder, Cancer, Myelodysplastic syndrome | Phase 2 Data readout | |
KER-065 Details Duchenne muscular dystrophy, Neuromuscular disease | Phase 1 Initiation | |
KER-047 (ALK2 inhibitor) Details Myelodysplastic syndrome, Myelofibrosis | Failed Discontinued | |
KER-047 (ALK2 inhibitor) Details Fibrodysplasia ossificans progressiva, Anemia | Failed Discontinued |